Your session is about to expire
← Back to Search
Investigational RSV vaccine MV-012-968 (Dosage 2) for Respiratory Syncytial Virus
Study Summary
This trial looks at the safety and effectiveness of a new RSV vaccine given as a nasal spray to healthy children 6-24 months old who have not previously been infected with RSV.
- Respiratory Syncytial Virus
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have a blocked nose, whether it's because of a structural issue, sinusitis, or any other reason.You have received an experimental RSV vaccine at any point in time.You have a long-term illness or condition like asthma, liver or kidney problems, recurrent infections, or a weakened immune system.
- Group 1: Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)
- Group 2: Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)
- Group 3: Placebo (Single-dose)
- Group 4: Placebo (Two-dose)
- Group 5: Dosage Group 1: RSV Vaccine Dosage 1
- Group 6: Dosage Group 2: RSV Vaccine Dosage 2
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the official government stance on RSV vaccine MV-012-968 (Dosage 2)?
"Because this is a Phase 1 trial, there is limited data supporting the safety and efficacy of Investigational RSV vaccine MV-012-968 (Dosage 2). Our team at Power rates it as a 1 on our scale."
Does this research project still need more test subjects?
"The clinical trial is presently looking for patients, as seen on clinicaltrials.gov. This study was originally posted on 6/3/2021 and updated as recently as 8/1/2022."
Does this experiment test the effects of the drug on patients that are above 40 years old?
"Children aged 6 months to 3 years old can participate in this trial, which is one of 52 clinical trials for minors and 91 for senior citizens."
For which type of person is this clinical study most appropriate?
"This clinical study is testing a medication for its efficacy in treating respiratory syncytial virus (RSV) in infants and toddlers. The age range of eligible patients is 6 months to 36 months old, and the team is looking to recruit 63 total participants."
What is the main goal of this research?
"The primary outcome that sponsors, Meissa Vaccines Inc., plan to measure is Adverse Events that require medical attention. This study will also compare pre and post-vaccination data on RSV F-specific Immunoglobulin A (IgA) concentrations in order to determine the efficacy of MV-012-968."
How many people are included as test subjects in this research?
"The trial needs 63 participants that match the clinical study's inclusion criteria. The sponsor, Meissa Vaccines, Inc., will run the experiment from different locations including MedPharmics in Metairie, Louisiana and Aventiv Research in Columbus, Ohio."
Share this study with friends
Copy Link
Messenger